Merck Represented the DRIVE-AHEAD Study of Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Doravirine

Merck company represented  the DRIVE-AHEAD study of the non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine in one pill, which should be taken once in a day before or after meal at the 9th International AIDS Society Conferecnce on HIV Science (IAS2017). The conference took place in the end of july in Paris.

NNRTI doravirine showed good results in the third phase of DRIVE-AHEAD study - actually it has smaller amount of side-effects. About 730 people were involved in the study, with the average age of 30 years and without using antiretroviral therapy before. People were divided into two groups and the group of NNRTI doravirine showed more than 80% of undetectable viral load with few side-effects like dizziness, insomnia.

Doravirine is a novel, once-daily NNRTI for first-line treatment with consistent efficacy regardless of baseline viral load and favourable tolerability and safety profile in 2 Phase 3 clinical trials," - concluded Kathleen Squires of Thomas Jefferson University, one of the investigators of the phase 3 DRIVE-AHEAD study.